16 Sep 2021
FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
Author: admintech | Filed under: Press ReleaseCHICAGO, Sept. 16, 2021 /PRNewswire/ — COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND)…